Optimizing Outcomes in HR+/HER2-Metastatic Breast Cancer: Molecular Testing and Targeted Strategies - Episode 1

Clinical Perspectives on Biomarker Testing in mBC

,

Now Viewing
EP. 1: Clinical Perspectives on Biomarker Testing in mBC
EP. 2: Repeat Biomarker Testing in mBC: Navigating the Rapidly Evolving Treatment Landscape
EP. 3: Selecting the Optimal CDK4/6 Regimen for First-Line Therapy
EP. 4: Clinical Considerations for CDK4/6 Inhibition Beyond Progression
EP. 5: Expert Insights: Managing Patients with PIK3CA Mutations
EP. 6: Navigating Treatment Selection in Patients with Both ESR1 and PIK3CA Mutations and Expert Perspective for Integrating Oral SERDs into Clinical Practice
EP. 7: The Emerging Role of Triplet Therapy in mBC: Opportunities and Challenges
EP. 8: The Evolving Landscape of mBC Treatment: Unmet Needs and Future Predictions

Video content above is prompted by the following:

  • Dr. O’Shaughnessy to Dr. Conlin: What is your approach to biomarker testing in metastatic breast cancer?
    • Which biomarkers are you routinely testing for?​
    • When are you testing your patients? (e.g. upfront, at progression) ​
    • Do you opt for tissue or liquid biopsy?

Related Content:

Optimizing Outcomes in HR+/HER2-Metastatic Breast Cancer: Molecular Testing and Targeted Strategies